Immediate Impact
23 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Works of Shi‐Xun Lu being referenced
PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.
2021
Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Shi‐Xun Lu | 110 | 86 | 31 | 96 | 21 | 247 | |
| Ariel E. Birnbaum | 110 | 115 | 22 | 58 | 25 | 268 | |
| Luciano Latini | 109 | 88 | 42 | 105 | 25 | 255 | |
| Phillipe Taniere | 109 | 92 | 37 | 94 | 23 | 263 | |
| Yibo Cai | 154 | 54 | 34 | 73 | 19 | 276 | |
| Hideo Tomihara | 128 | 63 | 20 | 134 | 23 | 273 | |
| Fenglin Zang | 69 | 44 | 31 | 87 | 22 | 200 | |
| Rie Nakatsuka | 86 | 69 | 15 | 75 | 21 | 234 | |
| Yanmei Gu | 118 | 66 | 18 | 43 | 18 | 208 | |
| Sara Hafezi‐Bakhtiari | 131 | 85 | 88 | 62 | 24 | 258 | |
| Sara E. Martin del Campo | 83 | 41 | 10 | 89 | 19 | 274 |
All Works
Loading papers...